Genetic variation in the bleomycin hydrolase gene and bleomycin-induced pulmonary toxicity in germ cell cancer patients
暂无分享,去创建一个
H. Groen | R. Hofstra | H. Hoekstra | J. Gietema | W. Sluiter | D. Sleijfer | C. Meijer | A. Suurmeijer | J. Nuver | M. L. Lutke Holzik | M. van Zweeden | H. Groen
[1] J. Scheys,et al. Genotyping for polymorphic drug metabolizing enzymes from paraffin-embedded and immunohistochemically stained tumor samples. , 2003, Pharmacogenetics.
[2] C. Amos,et al. Bleomycin hydrolase and a genetic locus within the MHC affect risk for pulmonary fibrosis in mice. , 2002, Human molecular genetics.
[3] H. Norppa,et al. Genetic polymorphisms of DNA repair and xenobiotic-metabolizing enzymes: role in mutagen sensitivity. , 2002, Carcinogenesis.
[4] S. Sleijfer. Bleomycin-induced pneumonitis. , 2001, Chest.
[5] Y. Ouchi,et al. Lack of association between bleomycin hydrolase gene polymorphism and Alzheimer's disease in Japanese people , 1999, Annals of neurology.
[6] G. Homanics,et al. The neutral cysteine protease bleomycin hydrolase is essential for epidermal integrity and bleomycin resistance. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[7] J. Haines,et al. Association between bleomycin hydrolase and Alzheimer's disease in caucasians , 1998, Annals of neurology.
[8] S. Kaye,et al. Fatal bleomycin pulmonary toxicity in the west of Scotland 1991-95: a review of patients with germ cell tumours. , 1998, British Journal of Cancer.
[9] S. DeKosky,et al. Bleomycin hydrolase is associated with risk of sporadic Alzheimer's disease , 1998, Nature Genetics.
[10] J. Lazo,et al. Essential binding and functional domains of human bleomycin hydrolase. , 1998, Biochemistry.
[11] R. Ferrell,et al. Genomic structure and genetic mapping of the human neutral cysteine protease bleomycin hydrolase. , 1997, Cancer research.
[12] L. Collette,et al. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] D. Payan,et al. Human bleomycin hydrolase: molecular cloning, sequencing, functional expression, and enzymatic characterization. , 1996, Biochemistry.
[14] E. Campo,et al. Cloning and expression analysis of human bleomycin hydrolase, a cysteine proteinase involved in chemotherapy resistance. , 1996, Cancer research.
[15] S. Sleijfer,et al. Enhanced effects of bleomycin on pulmonary function disturbances in patients with decreased renal function due to cisplatin. , 1996, European journal of cancer.
[16] S. Sleijfer,et al. Decrease in pulmonary function during bleomycin-containing combination chemotherapy for testicular cancer: not only a bleomycin effect. , 1995, British Journal of Cancer.
[17] S. Kaye,et al. The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinoma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] V. Harvey,et al. The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinoma. Australasian Germ Cell Trial Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] R. Dorr,et al. Bleomycin pharmacology: mechanism of action and resistance, and clinical pharmacokinetics. , 1992, Seminars in oncology.
[20] D. Dearnaley,et al. Combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for metastatic testicular teratoma: long-term follow-up. , 1991, European journal of cancer.
[21] D. White,et al. Bleomycin-induced pulmonary toxicity. , 1990, Clinics in chest medicine.
[22] L. Einhorn,et al. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] J. Lazo,et al. Alterations in pulmonary protective enzymes following systemic bleomycin treatment in mice. , 1988, Biochemical pharmacology.
[24] Shirley A. Miller,et al. A simple salting out procedure for extracting DNA from human nucleated cells. , 1988, Nucleic acids research.
[25] D. Stover,et al. Severe bleomycin-induced pneumonitis. Clinical features and response to corticosteroids. , 1984, Chest.
[26] J. Lazo,et al. Lack of metabolism as the biochemical basis of bleomycin-induced pulmonary toxicity. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[27] S. Crooke,et al. Effects of variations in renal function on the clinical pharmacology of bleomycin administered as an iv bolus. , 1977, Cancer treatment reports.
[28] I. Adamson,et al. The pathogenesis of bleomycin-induced pulmonary fibrosis in mice. , 1974, The American journal of pathology.
[29] J. Holland,et al. Microbiological assay of bleomycin: Inactivation, tissue distribution, and clearance , 1974, Cancer.
[30] T. Takeuchi,et al. New antibiotics, bleomycin A and B. , 1966, The Journal of antibiotics.
[31] C. Collis. Lung damage from cytotoxic drugs , 2004, Cancer Chemotherapy and Pharmacology.
[32] D. Dearnaley,et al. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[33] H. Sluiter,et al. Natural course of bleomycin-induced pneumonitis. A follow-up study. , 1987, The American review of respiratory disease.